New study headed by scientists at The University of Texas MD Anderson Cancer Centre offers a better knowledge of the evolution of the tumour microenvironment.
Immune checkpoint inhibitors, which unleash the immune response against tumor cells, have revolutionised cancer treatment; however, the medications aren't effective in a large number of patients, including those with colorectal cancer.
